News
LUT014 works by paradoxically reactivating MAPK, a key signaling pathway in the skin that anti-EGFR therapies shut down.
1don MSN
A new topical gel called LUT014 successfully reduced the severity of a painful acne‐like rash that commonly occurs as a side effect of targeted therapy with epidermal growth factor receptor (EGFR) ...
Researchers from the UCLA Health Jonsson Comprehensive Cancer Center and The University of Texas MD Anderson Cancer Center ...
1d
News-Medical.Net on MSNNew topical gel reduces painful rash from colorectal cancer treatmentResearchers from the UCLA Health Jonsson Comprehensive Cancer Center and The University of Texas MD Anderson Cancer Center have demonstrated that a novel topical BRAF inhibitor gel called LUT014 ...
“The findings offer the first real solution in two decades for managing this rash, which frequently impacts patients receiving targeted therapies for colorectal cancer,” said study co-author ...
"The findings offer the first real solution in two decades for managing this rash, which frequently impacts patients receiving targeted therapies for colorectal cancer," said study co-author Zev ...
HPV16 seropositivity is relatively common before anal cancer diagnosis. Anal cancer is a rare type of cancer that affects the anus (the opening through which stool leaves the body) or nearby areas ...
HPV16 seropositivity is relatively common before anal cancer diagnosis. Anal cancer is a rare type of cancer that affects the anus (the opening through which stool leaves the body) or nearby areas, ...
Cancer survivors say that first you must let the emotions out, find your support system, and live your life. “People that are strong cry, it’s the weak ones who try to hold it in,” says Evelyn ...
Other side effects from radiation that can lower your desire for sex include: Fatigue Nausea and vomiting Changes in how you look, such as rashes, hair loss ... cervical, bladder, colon, and rectal ...
Furthermore, those diagnosed with marijuana addiction before they were stricken with colon cancer were 24.4 times more likely ...
Emma Weston joined the clinical trial after running out of treatment options. For two years, she's been cancer free.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results